Genetic beta-blockade
What are the implications of an exciting discovery of intrinsic genetic beta-blockade common to 40% of people of African ancestry?

Dr Eric Topol invites you to share your opinions.

Click here to view the video blog and join the discussion.

HeartWire clips
On moving to industry: Interview with Dr Terry Ferguson
In conversation with heartwire news and features editor Larry Husten, Dr Terry Ferguson muses on changes to daily life, decision making processes, and patient care from a different perspective resulting from his new position in industry.
The Cardiology Show
Surrogate end points on trial: ENHANCE and other controversies
Part 2 is now live!
Nine of the world's top cardiologists gathered in Chicago to take on the issues raised by data released at the American College of Cardiology Scientific Sessions.

Dr Valentin Fuster moderates this frank and sometimes heated discussion on the results of ENHANCE, STRADIVARIUS, ONTARGET, and PERISCOPE, and the questions they raise about the responsibility of industry and the relevance of surrogate end points.
Forum
Smoking ban?
Read about our forum moderator's heroic and sometimes comic efforts to get a smoking ban passed by her city council in tobacco country.
Thumbs up, thumbs down
Controversies: ENHANCE and ACCORD
Clinical trials are under attack and in the headlines. What is the proper role of the investigators? What are the responsibilities of industry? Join Drs Eric J Topol and Robert M Califf in a discussion of the many issues surrounding ENHANCE and ACCORD.
Question
Do you think the ACC and SCAI should continue to combine their annual meetings in future years?
(See:Arranged marriage: Funding and "cultural differences" may dictate whether SCAI-ACC/i2 stay hitched)
No
Yes
Vote








Clinical cardiology  >  Atherothrombosis
Lost in translation: US and European guidelines for the pharmacologic management of ACS
Apr 10, 2008 14:00 EDT / If we're all looking at the same data, why do the European and US guidelines for the treatment of ACS differ in terms of initiation, dosing, and choices of pharmacological therapies? Drs Ohman, Montalescot, Pollack and Fox discuss the similarities and differences.
Antiplatelet therapy for atherothrombotic disease: Translating the evidence from clinical trial into practice
Feb 29, 2008 10:54 EST / This program will review the guidelines recommendations for and actual use of antiplatelet therapy in patients with atherothrombotic disease, practical issues in the use of antiplatelet therapy, and new trials of antiplatelet agents
Recent clinical trial data on adjunctive pharmacology in ACS patients undergoing PCI
Dec 27, 2007 12:30 EST / What is the future of adjunctive pharmacology given the results of the HORIZONS and TRITON trials?
Risk/benefit or benefit/risk: Trading safety for efficacy with antiplatelet agents
Dec 20, 2007 18:00 EST / Trading safety for efficacy with antiplatelet agents
Antiplatelet Therapy Across the Cardiovascular Risk Spectrum
Nov 26, 2007 10:00 EST / Drs Berger, Faxon and Steinhubl sddress clinical challenges in the management of patients with suspected ACS/ST-elevation myocardial infarction and cecognize the clinical implications of variability in response to antiplatelet agents.
PCI Today: Insights into Short and Long-Term Risk Reduction With Antiplatelet Therapy
Nov 8, 2007 13:30 EST / Are you aware of the latest guidelines, definitions and best practices? Straight from TCT 2007: Drs Grines, Cannon, Cutlip, and Mehta address gaps in current practice, explain challenges in the use of antiplatelet therapy, and discuss recently released definitions and guidelines for care.
Managing atherothrombotic risk: Early impact and long-term benefit of antiplatelet therapy
Oct 9, 2007 11:45 EDT / This program delivers evidence-based education, debate on the issues, data from randomized trials, observational data, and objective opinions from leaders in cardiology on the subject of antiplatelet therapies and their appropriate use in atherothrombosis.
Update on combination antiplatelet therapy
Jul 31, 2007 09:30 EDT / This program discusses the optimal use of combination antiplatelet therapy in non-ST elevation ACS, both in the acute and long-term setting. Additionally, the program will touch upon the early use of combination antiplatelet therapy in the setting of STEMI. Referencing the recent joint statement on DES by the Canadian Association of Interventional Cardiologists and the Canadian Cardiovascular Society, the program will also discuss optimal duration of dual antiplatelet therapy, strategies to prevent early discontinuation, and potential management strategies for patients who may require surgery while on dual antiplatelet therapy.
Looking Forward: Acute and Long-Term Antiplatelet Therapies
Apr 10, 2007 16:00 EDT / Antiplatelet therapy is the mainstay of comprehensive care for a broad spectrum of patients with atherothrombotic disease. Join Dr. Peter Berger as he leads an expert multidisciplinary panel of Drs. Ferguson, Pollack, and Simon in discussing case studies involving acute and long-term antiplatelet therapies.
Antithrombotic therapy in STEMI: What happened at AHA 2006?
Nov 27, 2006 10:00 EST / What is the ideal antithrombotic therapy for the management of STEMI patients? Please join Dr Antman and an expert panel as they discuss the latest clinical trial data from the AHA 2006 Scientific Sessions regarding the management of STEMI patients.


CME provider: Medscape.
The Atherothrombosis clinical theme is supported by an educational grant from sanofi-aventis and Bristol Myers-Squibb.
More on the Atherothrombosis clinical theme